原发纵隔大B细胞淋巴瘤的临床特征及治疗分析  

Clinical Characteristics and Prognosis Analysis of Primary Mediastinal Large B Cell Lymphoma

作　　者：于卫卫[1] 王华庆[1] 钱正子[1] 崔秀珍[1] 郝希山[1] 

机构地区：[1]天津医科大学附属肿瘤医院淋巴瘤科中美淋巴血液诊治中心天津市肿瘤防治重点实验室,天津300060

出　　处：《肿瘤防治研究》2011年第6期647-650,共4页Cancer Research on Prevention and Treatment

摘　　要：目的分析原发纵隔大B细胞淋巴瘤(PMLBCL)的临床特征,探讨其诊治要点及预后因素。方法回顾性分析1999年10月—2009年5月天津市肿瘤医院淋巴肿瘤科收治的25例PMLBCL的临床特点,绘制生存曲线、进行预后相关性分析及探讨不同治疗模式对患者生存期的影响。结果 5年总生存率(OS)和无进展生存率(PFS)分别为56.7%和54.7%。18例采用化放疗联合,7例单纯化疗,两组2年PFS分别为57.1%、53.6%,差异无统计学意义(P>0.05),单因素分析显示国际预后指数(IPI)评分高、特别是LDH高于正常值上限的两倍(LDH≥2ULN)为预后不良因素,但多因素分析结果显示两者均不是独立的预后因素。结论 IPI评分和LDH≥2ULN与PMLBCL的预后有关,但两者均不是独立的预后因素。本组资料显示化放疗联合较单纯化疗未能改善预后。Objective To explore the clinical characteristics,treatment patterns and prognostic factors of primary mediastinal large B cell lymphoma（PMLBCL）.Methods Clinical records of 25 PMLBCL patients who were admitted at department of lymphoma of Tianjin medical university cancer hospital,from October 1999 to May 2009,to evaluate the influence of clinical characteristics and treatment modality on survival.Results The 5-year overall survival（OS） and progress free survival（PFS）were 56.7% and 54.7%,respectively.Eighteen patients accepted chemoradiotherapy and 7 patients accepted chemotherapy alone.The 2-year PFS were 57.1% and 53.6%,respectively,the outcome had not significant difference（P0.05）.In univariate analysis,only international prognostic index（IPI）and LDH≥2ULN（upper limit of normal）were found to be the prognostic factors associated with overall surviva1 in PMLBCL.But in multivariate analysis,neither were independent prognostic factors.Conclusion IPI and LDH≥2ULN were associated with the prognosis of PMLBCL.But neither was independent prognostic factors in PMLBCL.Compared with chemotherapy,chemoradiotherapy did not show a better response.

关 键 词：淋巴瘤 大B细胞 临床特征 放化疗联合 预后 

分 类 号：R733.4[医药卫生—肿瘤]